230 related articles for article (PubMed ID: 12905659)
1. [Architecture, influencing factors, and sensitivity to antifungal agents of Candida biofilm].
Sun QN; Fang K
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Aug; 24(4):385-8. PubMed ID: 12905659
[TBL] [Abstract][Full Text] [Related]
2. [Biofilm production and antifungal susceptibility patterns of Candida species].
Yücesoy M; Karaman M
Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
[TBL] [Abstract][Full Text] [Related]
3. [In vitro biofilm formation and relationship with antifungal resistance of Candida spp. isolated from vaginal and intrauterine device string samples of women with vaginal complaints].
Calışkan S; Keçeli Özcan S; Cınar S; Corakçı A; Calışkan E
Mikrobiyol Bul; 2011 Oct; 45(4):697-706. PubMed ID: 22090300
[TBL] [Abstract][Full Text] [Related]
4. The expression of genes involved in the ergosterol biosynthesis pathway in Candida albicans and Candida dubliniensis biofilms exposed to fluconazole.
Borecká-Melkusová S; Moran GP; Sullivan DJ; Kucharíková S; Chorvát D; Bujdáková H
Mycoses; 2009 Mar; 52(2):118-28. PubMed ID: 18627475
[TBL] [Abstract][Full Text] [Related]
5. In vitro method to study antifungal perfusion in Candida biofilms.
Samaranayake YH; Ye J; Yau JY; Cheung BP; Samaranayake LP
J Clin Microbiol; 2005 Feb; 43(2):818-25. PubMed ID: 15695686
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
7. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance.
Jabra-Rizk MA; Shirtliff M; James C; Meiller T
FEMS Yeast Res; 2006 Nov; 6(7):1063-73. PubMed ID: 17042756
[TBL] [Abstract][Full Text] [Related]
8. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces.
Samaranayake YH; Cheung BP; Parahitiyawa N; Seneviratne CJ; Yau JY; Yeung KW; Samaranayake LP
Arch Oral Biol; 2009 Feb; 54(2):115-26. PubMed ID: 19038377
[TBL] [Abstract][Full Text] [Related]
10. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole.
Khan ZU; Al-Sweih NA; Ahmad S; Al-Kazemi N; Khan S; Joseph L; Chandy R
J Clin Microbiol; 2007 Jun; 45(6):2025-7. PubMed ID: 17428940
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms.
Nailis H; Vandenbosch D; Deforce D; Nelis HJ; Coenye T
Res Microbiol; 2010 May; 161(4):284-92. PubMed ID: 20170727
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
13. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
14. Biofilm inhibition by Cymbopogon citratus and Syzygium aromaticum essential oils in the strains of Candida albicans.
Khan MS; Ahmad I
J Ethnopharmacol; 2012 Mar; 140(2):416-23. PubMed ID: 22326355
[TBL] [Abstract][Full Text] [Related]
15. Biofilms of Candida spp. from the ocular conjunctiva of horses with reduced azole susceptibility: a complicating factor for the treatment of keratomycosis?
Brilhante RSN; Bittencourt PV; de Souza Collares Castelo-Branco D; de Melo Guedes GM; de Oliveira JS; Alencar LP; de Aguiar Cordeiro R; Pinheiro M; Nogueira-Filho EF; de Aquino Pereira-Neto W; Sidrim JJC; Rocha MFG
Vet Ophthalmol; 2017 Nov; 20(6):539-546. PubMed ID: 28417524
[TBL] [Abstract][Full Text] [Related]
16. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.
Yang YL; Li SY; Cheng HH; Lo HJ;
BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438
[TBL] [Abstract][Full Text] [Related]
17. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
18. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
19. [Antimicrobial drug therapy and microbial sensitivity tests--antifungal agents and microbial sensitivity tests].
Yamaguchi H
Rinsho Byori; 1997 Jul; Suppl 105():182-90. PubMed ID: 9379538
[No Abstract] [Full Text] [Related]
20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
